Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neurocrine Biosciences (NBIX) Non Operating Income (2016 - 2025)

Neurocrine Biosciences' Non Operating Income history spans 16 years, with the latest figure at $28.5 million for Q4 2025.

  • For Q4 2025, Non Operating Income rose 38.35% year-over-year to $28.5 million; the TTM value through Dec 2025 reached $86.3 million, up 202.13%, while the annual FY2025 figure was $86.3 million, 202.13% up from the prior year.
  • Non Operating Income reached $28.5 million in Q4 2025 per NBIX's latest filing, down from $52.8 million in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $52.8 million in Q3 2025 to a low of -$78.0 million in Q2 2022.
  • Average Non Operating Income over 5 years is $2.3 million, with a median of $10.5 million recorded in 2022.
  • Peak YoY movement for Non Operating Income: tumbled 1371.7% in 2022, then surged 712.31% in 2025.
  • A 5-year view of Non Operating Income shows it stood at $22.5 million in 2021, then plummeted by 35.56% to $14.5 million in 2022, then surged by 230.34% to $47.9 million in 2023, then plummeted by 56.99% to $20.6 million in 2024, then surged by 38.35% to $28.5 million in 2025.
  • Per Business Quant, the three most recent readings for NBIX's Non Operating Income are $28.5 million (Q4 2025), $52.8 million (Q3 2025), and $13.9 million (Q2 2025).